Becton Dickinson and Company (BDX)
Health Care2 articles
Market Mood
Becton Dickinson (BDX) Stock Sees 6% Rise After Earnings Beat
Becton, Dickinson and Company (NYSE: BDX) experienced a nearly 6% increase in stock price following a strong earnings report on May 7. The company raised its full-year earnings forecast, highlighting excellent execution across its medical supply and technology divisions. Jim Cramer noted this was the lowest valuation level he has seen for the stock, suggesting potential further upside. Despite near-term challenges from increased AI spending, BDX's positive earnings reflect strong operational performance and market positioning.
Read More
Becton Dickinson (BDX) Price Target Trimmed to $159 by Piper Sandler
Piper Sandler has reduced the price target for Becton, Dickinson and Company (BDX) from $170 to $159 while maintaining a Neutral rating. This adjustment was made on April 17, 2026, to align with management's revenue growth guidance. Additionally, RBC Capital Markets lowered its price target for BDX to $175 from $195, citing stable fundamentals in the MedTech sector. Both firms note that current sentiment around BDX may create investment opportunities, but they expect the stock to remain range-bound due to a lack of clear catalysts.
Read More